Skip to main content
Fig.Ā 2 | Malaria Journal

Fig.Ā 2

From: A single rapamycin dose protects against late-stage experimental cerebral malaria via modulation of host immunity, endothelial activation and parasite sequestration

Fig.Ā 2

Rapamycin treatment inhibits parasite sequestration. C57BL6 mice were infected with transgenic luciferase-expressing P. berghei ANKA on day 0, and treated with 5Ā mg/kg of rapamycin (R) or vehicle (V) on day 4 post infection. Luciferase activity was measured in perfused tissues at day 6. a Ex vivo luciferase activity indicative of parasite sequestration in lung (a) andĀ white adipose tissue (b); perigonadal, PgWAT; subcutaneous, ScWAT). c, d Immunoblot and quantification of CD36 protein expression in PgWAT (c) and lung (d) of day 6 infected mice treated on day 4 with vehicle or rapamycin (5Ā mg/kg). Data are meanĀ Ā±Ā SEM; nĀ =Ā 5/group

Back to article page